CN105395793A - Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris - Google Patents
Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris Download PDFInfo
- Publication number
- CN105395793A CN105395793A CN201510719808.XA CN201510719808A CN105395793A CN 105395793 A CN105395793 A CN 105395793A CN 201510719808 A CN201510719808 A CN 201510719808A CN 105395793 A CN105395793 A CN 105395793A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine composition
- parts
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses application of a traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris. The composition is soft capsules prepared through a conventional preparation technology with ginkgo leaves, herba erigernotis, salviae miltiorrhizae, borneol, hawthorn fruits, gynostemma pentaphyllum, panax notoginseng and garlic as raw materials. The composition is prepared according to Miao medicine theories. The preparation is good in medicine component dissolution, high in bioavailability, little in dose and stable in drug property. The composition can be used for treating thoracic obstruction, breast pain, chest distress, hard breath, palpitation and the like caused by qi stagnation and blood stasis. The traditional Chinese medicine preparation has the functions of promoting blood circulation to remove blood stasis and tonifying qi and stopping pain.
Description
Technical field
The present invention relates to a kind of Chinese medicine purposes, particularly a kind of Chinese medicine composition for the preparation of the application in treatment chronic stable angina medicine.
Background technology
Angina pectoris is the serious harm mankind particularly commonly encountered diseases of middle-aged and elderly people and frequently-occurring diseases, at present not yet good radical-ability medicine.Current domestic relieve chronic stable angina pectoris outbreak multiselect nitroglycerine tablets and FUFANG DANSHEN DIWAN are main, but nitrate esters preparation easily produces toleration, there will be the untoward reaction such as dizziness, headache, flush after some patient takes, after stopping using, have rebound phenomenon.In addition, the medicine of existing treatment chronic stable angina and dosage form only can meet certain market demand.Therefore, usually need clinically one can relief of symptoms, to remove patient painful, successful, the medicine that side effect is little and easy to use.
Chinese medicine demonstrates wide application prospect with advantages such as its Mutiple Targets, too many levels intervention and safeties relatively preferably in anginal control.Compared with prior art, the present invention is a kind of medicine made according to Seedling medicine theory, and it adopts Chinese medicinal herbs comparatively common in the localities as raw material, with low cost.There is blood circulation promoting and blood stasis dispelling, the function of promoting the circulation of QI to relieve pain and good clinical therapeutic efficacy.
Summary of the invention
Chinese medicine composition of the present invention is for the preparation of the application in treatment chronic stable angina medicine, it is characterized in that this Chinese medicine composition is the crude drug by following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 45-55 part, Herba Erigerontis 25-35 part, Radix Salviae Miltiorrhizae 45-55 part, Borneolum Syntheticum 0.5-1.5 part, Fructus Crataegi 35-45 part, Herb Gynostemmae Pentaphylli 25-35 part, Radix Notoginseng 15-25 part, Bulbus Allii 35-45 part.
Chinese medicine composition can be the crude drug by following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 48-53 part, Herba Erigerontis 28-32 part, Radix Salviae Miltiorrhizae 48-53 part, Borneolum Syntheticum 0.7-13 part, Fructus Crataegi 38-43 part, Herb Gynostemmae Pentaphylli 28-32 part, Radix Notoginseng 18-22 part, Bulbus Allii 35-45 part.
Chinese medicine composition can be by with the crude drug of following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 50 parts, Herba Erigerontis 30 parts, Radix Salviae Miltiorrhizae 50 parts, Borneolum Syntheticum 1 part, Fructus Crataegi 40 parts, Herb Gynostemmae Pentaphylli 30 parts, Radix Notoginseng 20 parts, 40 parts, Bulbus Allii.
The preparation method of Chinese medicine composition is: by Folium Ginkgo ethanol extraction, makes dried cream powder broken after polyamide resin column eluting, simultaneously Bulbus Allii to soak after distillation with beta-schardinger dextrin-bag and, Radix Salviae Miltiorrhizae ethanol extraction; Then the Radix Notoginseng after Herba Erigerontis, Fructus Crataegi, Herb Gynostemmae Pentaphylli and pulverizing is mixed, decocting and concentrating, cream processed pulverizes, add the Folium Ginkgo after extraction, Radix Salviae Miltiorrhizae, Bulbus Allii and pharmaceutic adjuvant, make soft capsule preparation.
The present invention is a kind of medicine made according to Seedling medicine theory.Preparation medicine composition of the present invention stripping is good, bioavailability is high, dose is little, the property of medicine is stable.Can be used for the thoracic obstruction that treatment qi depression to blood stasis causes, disease sees chest pain, uncomfortable in chest, breathes hard, cardiopalmus etc.This Chinese medicine preparation has blood circulation promoting and blood stasis dispelling, the effect of QI invigorating pain relieving.
detailed description of the invention:
embodiment one.
Get Folium Ginkgo 50kg, Herba Erigerontis 30kg, Radix Salviae Miltiorrhizae 50kg, Borneolum Syntheticum 1kg, Fructus Crataegi 40kg, Herb Gynostemmae Pentaphylli 30kg, Radix Notoginseng 20kg, Bulbus Allii 40kg as raw material.Get Radix Notoginseng powder and be broken into fine powder, cross 150 mesh sieves and obtain Radix Notoginseng fine powder 3kg, all the other are Radix Notoginseng coarse powder.By Radix Notoginseng fine powder discontinuous sterilization 1-2 hour, cultivate 24 hours, then continuous sterilization 3 times, obtaining Radix Notoginseng fine powder after drying is A product.Get borneol and grinding and become impalpable powder, cross 150 mesh sieves; Get Bulbus Allii material, add 6 times of water gagings, boil, collect distillate, separation and Extraction Oleum Bulbus Allii (about obtaining 1kg); Get Radix Salviae Miltiorrhizae and add ethanol, reflux, extract, 2 times, each 1.5h, filter, merge 2 filtrates, reclaim ethanol, simmer down to relative density is 1.20, and drying under reduced pressure, is ground into impalpable powder, and cross 150 mesh sieves (about obtaining 1.5kg), medicinal residues are for subsequent use; By all the other four raw materials and Radix Notoginseng coarse powder, Radix Salviae Miltiorrhizae decoction dregs mixing, add 4 times of water gagings, decoct 2 times, each 2 hours, filter, merging filtrate, leave standstill 12 hours, getting supernatant, to be evaporated to relative density be 1.15, adds ethanol, stir evenly, make alcohol content be 70%, leave standstill 24 hours, get supernatant, reclaim ethanol, being concentrated into relative density is 1.2, drying under reduced pressure, is ground into impalpable powder, crosses 150 mesh sieves; Above-mentioned impalpable powder, volatile oil and adjuvant are added in vegetable oil, is fully uniformly mixed, be pressed into soft capsule; Drying, packaging, get product capsule.By 0.4 gram every, every day three times, each 2-4 grain three months is 1 course for the treatment of.
embodiment two.
Get Folium Ginkgo 48kg, Herba Erigerontis 28kg, Radix Salviae Miltiorrhizae 52kg, Borneolum Syntheticum 1.2kg, Fructus Crataegi 38kg, Herb Gynostemmae Pentaphylli 32kg, Radix Notoginseng 19kg, Bulbus Allii 42kg as raw material, can be made into finished capsule product by embodiment 1 method.
embodiment three.
Get Folium Ginkgo 52kg, Herba Erigerontis 32kg, Radix Salviae Miltiorrhizae 48kg, Borneolum Syntheticum 0.8kg, Fructus Crataegi 41kg, Herb Gynostemmae Pentaphylli 28kg, Radix Notoginseng 21kg, Bulbus Allii 38kg as raw material, can be made into finished capsule product by embodiment 1 method.
The present invention also can be prepared into other dosage forms such as tablet, electuary, syrup by preparation process routinely.
For confirming that the product obtained has effective therapeutic effect, We conducted a series of clinical and experimental study.The main efficacy results that the present invention treats chronic stable angina is as follows:
1. patient and method
Chronic stable angina patient 394 example, carries out the Randomized controlled clinical study for the treatment of chronic stable angina.
Random experiment group and matched group distribute according to 1:1.Wherein test group gives Capsule YD, each 4, every day 3 times, oral, takes FUFANG DANSHEN DIWAN simulant simultaneously, takes 8 weeks continuously; Matched group gives FUFANG DANSHEN DIWAN, each 10 balls, every day 3 times, oral, takes Capsule YD simulant simultaneously, takes 8 weeks continuously.
Final test group completes 183 examples; Matched group completes 190 examples.Before two groups of patient treatments, the physical data such as age, sex, staging compares, the equal not statistically significant of difference (P>0.05).
observation index
2.1 angina pectorisobserve angina pectoris attacks number of times, persistent period, pain degree and nitroglycerin consumption, observation in every 4 weeks 1 time, adopts integration method.
exercise ECGin test, two groups respectively have 60 routine experimenters to carry out exercise stress electrocardiogram, each observation 1 time before and after test.
other observation index: homocysteine (HCY)
2.4 safety indexescomprise blood, urine, feces routine, liver function (ALT, AST, ALP, TBIL, GGT), renal function (BUN, Cr), coagulation function.
efficacy result
3.1 liang of group curative effect to treat angina pectoris compareeffective 82 examples of test group, effective 36 examples, invalid 73 examples, increase the weight of 5 examples, obvious effective rate 41.837%, total effective rate (effective+effectively) 60.204%; Matched group is respectively 78,31,86,3 examples, obvious effective rate 39.394%, total effective rate 55.051%, two groups of comparing difference not statistically significants (P>0.05).
treat the test that seesaws for two groups to compare (table 1-2)two groups of patients have 120 examples (test group 60 example, matched group 60 example) and have carried out exercise test.Result shows, more equal not statistically significant (P>0.05) between five index groups such as two groups of exercise durations, exercise induced ST decline 0.1mv time, exercise metabolism equivalent, maximum myocardial oxygen consumption, ST section change degree.Termination test reason to reach secondary amount, ST section changes into master, two groups of basic conditions are similar.
Table 1 the 8th week exercise stress electrocardiogram test stops reason
* note: some cases is because two or more reason stops.
The treatment of table 2 liang group seesaw test compare (mean ±
sd)
3.3 liang of group HCY comparitive studytwo groups have 162 examples (test group 77 example, matched group 85 example) the front HCY value for the treatment of and are greater than the range of normal value upper limit, and two groups of group difference not statistically significants (P>0.05), have comparability; Through the treatment of 8 weeks, test group HCY value decline 8.281 ± 16.665 μm of ol/L, rate of descent 21.4%, matched group decline 4.081 ± 16.283 μm of ol/L, rates of descent 6.3%, above index two groups of group differences have statistical significance (P<0.05).
blood fatfurther subgroup analysis is carried out to the patient of lipids single index exception, no difference of science of statistics between TC, HDL-C, TG group, but before and after in two groups of groups, comparing difference has statistical significance (P<0.05), points out two groups of curative effects similar.But in hypercholesterolemia patient, before and after two groups of LDL-C treatments, changing value and rate of change group difference all have statistical significance (P<0.05), and test group rate of descent is 25.8%, and matched group rate of descent is 7%, and test group is better than matched group greatly.Mean that the other diseases that this treatment chronic stable angina hyperlipidemia causes also has certain therapeutical effect, need to be furtherd investigate further.
, conclusionthe case that the medicine that the present invention relates to raises for T-CHOL before treatment and low density lipoprotein, LDL respectively has good curative effect, particularly suitable for the chronic stable angina patient with dyslipidemia, and improving in the blood HCY value of patient, medicine of the present invention is significantly better than FUFANG DANSHEN DIWAN, in general, medicine of the present invention is the active drug for the treatment of chronic stable angina, simultaneously in safety, result of the test shows that drug safety of the present invention is good, without obvious adverse reaction.
Claims (4)
1. a Chinese medicine composition is for the preparation of the application in treatment chronic stable angina medicine, it is characterized in that this Chinese medicine composition is the crude drug by following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 45-55 part, Herba Erigerontis 25-35 part, Radix Salviae Miltiorrhizae 45-55 part, Borneolum Syntheticum 0.5-1.5 part, Fructus Crataegi 35-45 part, Herb Gynostemmae Pentaphylli 25-35 part, Radix Notoginseng 15-25 part, Bulbus Allii 35-45 part.
2. according to claim 1 Chinese medicine composition for the preparation of the application in treatment chronic stable angina medicine, it is characterized in that this Chinese medicine composition is the crude drug by following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 48-53 part, Herba Erigerontis 28-32 part, Radix Salviae Miltiorrhizae 48-53 part, Borneolum Syntheticum 0.7-13 part, Fructus Crataegi 38-43 part, Herb Gynostemmae Pentaphylli 28-32 part, Radix Notoginseng 18-22 part, Bulbus Allii 35-45 part.
3. Chinese medicine composition according to claim 2 is for the preparation of the application in treatment chronic stable angina medicine, it is characterized in that this Chinese medicine composition is by with the crude drug of following weight proportion, conveniently the Chinese patent medicine that is prepared into of preparation process thereof: Folium Ginkgo 50 parts, Herba Erigerontis 30 parts, Radix Salviae Miltiorrhizae 50 parts, Borneolum Syntheticum 1 part, Fructus Crataegi 40 parts, Herb Gynostemmae Pentaphylli 30 parts, Radix Notoginseng 20 parts, 40 parts, Bulbus Allii.
4. the preparation method of the Chinese medicine composition as described in claim 1,2 or 3, is characterized in that: by Folium Ginkgo ethanol extraction, makes dried cream powder broken after polyamide resin column eluting, simultaneously Bulbus Allii to soak after distillation with beta-schardinger dextrin-bag and, Radix Salviae Miltiorrhizae ethanol extraction; Then the Radix Notoginseng after Herba Erigerontis, Fructus Crataegi, Herb Gynostemmae Pentaphylli and pulverizing is mixed, decocting and concentrating, cream processed pulverizes, add the Folium Ginkgo after extraction, Radix Salviae Miltiorrhizae, Bulbus Allii and pharmaceutic adjuvant, make soft capsule preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510719808.XA CN105395793A (en) | 2015-10-30 | 2015-10-30 | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510719808.XA CN105395793A (en) | 2015-10-30 | 2015-10-30 | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105395793A true CN105395793A (en) | 2016-03-16 |
Family
ID=55461788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510719808.XA Pending CN105395793A (en) | 2015-10-30 | 2015-10-30 | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395793A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481652A (en) * | 2017-09-12 | 2019-03-19 | 郑焕刚 | A kind of Chinese medicine and preparation method thereof for treating palpitation |
-
2015
- 2015-10-30 CN CN201510719808.XA patent/CN105395793A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481652A (en) * | 2017-09-12 | 2019-03-19 | 郑焕刚 | A kind of Chinese medicine and preparation method thereof for treating palpitation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN102145128A (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
| CN104013929B (en) | Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof | |
| CN102225100A (en) | Chinese medicinal formulation for treating cardiovascular and cerebrovascular diseases and preparation process of products thereof | |
| CN102091268A (en) | Medicament for treating allergic rhinitis and preparation method thereof | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN105326939A (en) | Traditional Chinese medicine for treating heart and cerebral vusculer diseases | |
| CN105395793A (en) | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris | |
| CN102228591B (en) | Preparation method of oral medicinal preparation for regulating menstruation and stopping pains | |
| CN101391044A (en) | External traditional Chinese medicine for treating zoster, herpes simplex or the other viral disease and preparation method thereof | |
| CN101019926A (en) | Chinese medicine for treating cardiac and cerebral vascular diseases and its prepn process | |
| CN103751547A (en) | Traditional Chinese medicinal composition for reducing blood lipid and preparation method thereof | |
| CN1166397C (en) | Medicine for treating cardiovascular and cerebrovascular system disease, apoplectic sequel | |
| CN105497351A (en) | Traditional Chinese medicine composition for treating facioplegia and preparation method thereof | |
| CN105920296A (en) | Traditional Chinese medicine preparation for adjuvant treatment of angina pectoris in qi-and-yin-deficiency type coronary heart diseases, and preparation method thereof | |
| CN105687543A (en) | External Chinese herba preparation for treating tumors | |
| CN101912537A (en) | Chinese medicinal preparation for treating cerebrovascular neuropathic pain | |
| CN100428942C (en) | Heart-nourishing and tranquilizing medicine and its prepn process | |
| CN101239140A (en) | Chinese medicine for treating psoriasis | |
| CN106138637B (en) | Traditional Chinese medicine composition for promoting blood circulation, removing blood stasis, resisting rheumatism and relieving pain and preparation method thereof | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105395794A (en) | Application of traditional Chinese medicine to anti-oxidation medicine preparation | |
| CN106853193A (en) | It is a kind of to treat Chinese medicine of rheumatoid arthritis and preparation method thereof | |
| CN101194963B (en) | Process for preparing medicine for treating headache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160316 |